Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (11-20 of 436) with videos related to

Pageof 44
Sort By:
The New England Journal of Medicine|July 20, 2012
Two centuries of assessing drug risksJerry Avorn
The New England Journal of Medicine|September 9, 2005
FDA standards--good enough for government work?Jerry Avorn
JAMA|February 23, 2013
Approval of a tuberculosis drug based on a paradoxical surrogate measureJerry Avorn
The New England Journal of Medicine|August 19, 2007
Keeping science on top in drug evaluationJerry Avorn
The New England Journal of Medicine|February 22, 2018
The Psychology of Clinical Decision Making - Implications for Medication UseJerry Avorn
Annals of Internal Medicine|September 3, 2014
Rethinking the use of physicians as hired expert lecturersJerry Avorn
The New England Journal of Medicine|June 17, 2026
Products That Pose Health Risks - Can Litigation Protect Us When Government Fails?Jerry Avorn
Science (New York, N.Y.)|July 30, 2005
Sending pharma better signalsJerry Avorn
The New England Journal of Medicine|December 17, 2025
The 25th Anniversary of a Nearly Unknown Health Policy Turning PointJerry Avorn
JAMA|October 14, 2010
Medication use in older patients: better policy could encourage better practiceJerry Avorn
Pageof 44

Showing results (11-20 of 436) with videos related to

Sort By:
Pageof 44
The New England Journal of Medicine|July 20, 2012
Two centuries of assessing drug risksJerry Avorn
The New England Journal of Medicine|September 9, 2005
FDA standards--good enough for government work?Jerry Avorn
JAMA|February 23, 2013
Approval of a tuberculosis drug based on a paradoxical surrogate measureJerry Avorn
The New England Journal of Medicine|August 19, 2007
Keeping science on top in drug evaluationJerry Avorn
The New England Journal of Medicine|February 22, 2018
The Psychology of Clinical Decision Making - Implications for Medication UseJerry Avorn
Annals of Internal Medicine|September 3, 2014
Rethinking the use of physicians as hired expert lecturersJerry Avorn
The New England Journal of Medicine|June 17, 2026
Products That Pose Health Risks - Can Litigation Protect Us When Government Fails?Jerry Avorn
Science (New York, N.Y.)|July 30, 2005
Sending pharma better signalsJerry Avorn
The New England Journal of Medicine|December 17, 2025
The 25th Anniversary of a Nearly Unknown Health Policy Turning PointJerry Avorn
JAMA|October 14, 2010
Medication use in older patients: better policy could encourage better practiceJerry Avorn
Pageof 44